Tag: Africa

Posted on

Henley & Partners hosts the 17th Global Citizenship Conference in Dubai

LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) — More than 400 delegates from over 35 countries are expected to attend the 17th annual Global Residence and Citizenship Conference, which takes place next week (8-10 November) at the Shangri-La Hotel DIFC in Dubai, UAE.

Hosted by world-leading international citizenship and residence advisory firm Henley & Partners, this annual event has become the world’s largest and most significant conference on private wealth and investment migration, bringing together presidents, prime ministers, senior government ministers and officials, leading academics, private client advisors, wealth management professionals, and top-tier financial and business media.

The 2023 conference program features sophisticated, cutting-edge content on the major developments shaping investment migration and geopolitics today, offering delegates the opportunity to engage with the world’s leading minds and latest ideas around the central themes of global citizenship and interconnectivity.

Dr. Christian H. Kalin, Group Chairman of Henley & Partners, who will also be speaking at the conference, points out that there could not be a more relevant and necessary time to connect across borders as citizens of the world. “At a moment in our history when our world seems increasingly fractured and polarized, it is more important than ever for us to focus our minds on our shared humanity and how we can be stronger together. While it may mean different things to different people, global citizenship is based on the principle that we all have responsibilities to the world as a whole, rather than just our own local communities or countries. This conference aims to expand our horizons through global learning and understanding so that we can effect change in a more meaningful sense on both a small and larger scale.”

Notable key speakers at the conference include the Prime Ministers of Montenegro, H.E. Dr. Dritan Abazovic, and of Grenada, the Hon. Dickon Mitchell, as well as the former President and Speaker of the Parliament of the Maldives, the Hon. Mohamed Nasheed. CEO of the Dubai Economic Development Corporation, Hadi Badri, along with Prof. Dr. Christian Joppke of the Institute of Sociology at the University of Bern in Switzerland, Dr. Titus Gebel, President of the Free Cities Foundation in Germany, Prof. Dr. Khalid Koser, Executive Director of the Global Community Engagement and Resilience Fund, Chief Partnership Officer of Women in AI, Middle East, Debbie Botha, and Dr. Parag Khanna, Founder and CEO of Climate Alpha in Singapore, among many others. They all will share their perspectives on the key social, economic, political and environmental trends shaping our world.

Another highlight of the conference will be the 2023 Global Citizen Award Dinner on 9 November to honor a remarkable individual working to advance one of the global challenges affecting humanity today. Hosted in collaboration with the Swiss non-profit humanitarian organization Andan Foundation, this year’s laureate will be announced at the gala event and the net proceeds of the evening will be donated to the foundation which focuses on self-reliance of refugees through education, entrepreneurship, and employment.

Notes to Editors

For further information and media accreditation to attend the 17th annual Global Residence and Citizenship Conference, please contact:

Sarah Nicklin
Group Head of Public Relations
sarah.nicklin@henleyglobal.com
Mobile: +27 72 464 8965

About Henley & Partners

Henley & Partners is the global leader in residence and citizenship by investment. Each year, hundreds of wealthy individuals and their advisors rely on our expertise and experience in this area. The firm’s highly qualified professionals work together as one team in over 40 offices worldwide.

The concept of residence and citizenship by investment was created by Henley & Partners in the 1990s. As globalization has expanded, residence and citizenship have become topics of significant interest among the increasing number of internationally mobile entrepreneurs and investors whom we proudly serve every day.

Henley & Partners also runs the world’s leading government advisory practice for investment migration, which has raised more than USD 12 billion in foreign direct investment. Trusted by governments, the firm has been involved in strategic consulting and in the design, set-up, and operation of the world’s most successful residence and citizenship programs.
https://www.henleyglobal.com

GlobeNewswire Distribution ID 1000896628

Posted on

Pixalate Announces General Availability of Ad Fraud Prevention API with Pay-As-You-Go Pricing for Website, Mobile and Connected TV App Developers

With a few clicks, developers can now sign up and integrate Pixalate’s advertising fraud prevention technology into their apps and websites without signing long-term contracts

London, UK, Oct. 30, 2023 (GLOBE NEWSWIRE) — Pixalate, the global market-leading ad fraud protection, privacy, and compliance analytics platform, today announced general availability of its self-service Ad Fraud Prevention API. With no annual commitments or upfront costs, developers and publishers of all sizes can access Pixalate’s reliable and low-latency solution to easily scale and grow.

Pixalate APIs are powered by the company’s MRC-accredited Analytics platform. Accreditation areas include sophisticated invalid traffic (SIVT) detection & filtration for both display and video across Connected TV (CTV), mobile app, mobile web, and desktop.

Access to MRC-accredited ad fraud prevention tools has historically been limited to large, enterprise sized publishers & developers. Pixalate’s self-service API gives smaller developers an upper hand to scale their platforms by protecting existing ad revenue streams and fortifying the integrity of their advertising inventory against bad actors.

Using most globally-accepted credit cards, customers can sign up in minutes, choose the plan that’s right for them, and immediately incorporate Pixalate’s ad fraud prevention insights into their apps. Subscriptions start at $99 a month and give developers the freedom to adjust based on usage. When a customer exceeds a plan’s usage quota, consumption-based pricing kicks in without any interruption to the service.

Key Benefits Include: 

  • Reduce clawbacks. Protects publishers & developers’ revenue by taking steps to improve ad traffic quality.
  • Align with major exchanges. Enable developers to use the same ad fraud technology as major exchanges.
  • Combat ad fraud. Prevents 40+ types of invalid traffic (IVT) & fraud vectors that harm app traffic quality.
  • Prevent getting blocklisted. Bake fraud prevention into apps from the ground up.
  • Billing Dashboard. View real-time API usage and charges on the billing dashboard.
  • Ease of Integration. With just a few clicks, any developer can sign up with a freemium plan and begin integrating the APIs with a few lines of code.

API Input Parameters:

  • IP address: Analyzes an IP address (either IPv4 or IPv6) to check for any associated risks.
  • Device Identifier: Examines the device identifier to detect any abnormalities or signs of fraudulent activity.
  • User Agent: Evaluates the user agent data to identify potentially malicious software or bots.

API Output Parameters:

  • Fraud Risk Assessment: Subscribers can request a risk score from Pixalate’s servers to gauge the likelihood of an IP, Device ID, or User Agent being compromised or engaged in malicious activity.

Platforms Supported

  • Websites
  • Mobile (iOS, Android)
  • Connected TV (Roku, Fire TV, Samsung, LG, tvOS and more)

SDKs

  • iOS
  • Android

To learn more about the Ad Trust & Safety API suite, visit https://developer.pixalate.com.

About Pixalate
Pixalate is the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising. We work 24/7 to guard your reputation and grow your media value. Pixalate offers the only system of coordinated solutions across display, app, video, and CTV for better detection and elimination of ad fraud. Pixalate is an MRC-accredited service for the detection and filtration of sophisticated invalid traffic (SIVT) across desktop and mobile web, mobile in-app, and CTV advertising.

Media Contact: press@pixalate.com

Disclaimer

As used herein, and per the Media Rating Council, Inc. (MRC), “‘Fraud’ is not intended to represent fraud as defined in various laws, statutes and ordinances or as conventionally used in U.S. Court or other legal proceedings, but rather a custom definition strictly for advertising measurement purposes;” and “‘Invalid Traffic’ is defined generally as traffic that does not meet certain ad serving quality or completeness criteria, or otherwise does not represent legitimate ad traffic that should be included in measurement counts. Among the reasons why ad traffic may be deemed invalid is it is a result of non-human traffic (spiders, bots, etc.), or activity designed to produce fraudulent traffic.”

Press
Pixalate Inc.
press@pixalate.com

GlobeNewswire Distribution ID 8968701

Posted on

Impulse Dynamics Receives Full-Body MRI-Conditional Approval for Optimizer Smart Mini System

Reflecting Company Commitment to Innovation in Support of Patient Need

MARLTON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today it has received whole-body MRI-conditional approval for the Optimizer® Smart Mini system from the United States Food and Drug Administration (FDA). The Optimizer Smart Mini system delivers the company’s proprietary CCM® therapy. This conditional approval expands the product labeling to allow for full-body magnetic resonance (MRI) diagnostic imaging with 1.5 and 3.0 Tesla (T) scanners. The approval for use with full-body MRI covers new patients adopting CCM therapy as well as existing Optimizer Smart Mini users.

“We are pleased to receive approval for this important labeling change reflecting a necessary option for heart failure patients who likely receive multiple surgeries and benefit from the use of MRI imaging in the course of their treatment,” said Jason Spees, CEO of Impulse Dynamics. “This furthers our commitment to supporting the heart failure patients who benefit from important and life-changing CCM therapy with the Optimizer Smart Mini system.”

“Full body MRI capability is part of our promise to deliver an ongoing pace of innovation,” said David Prutchi, Ph.D., Chief Technology Officer, Impulse Dynamics. “This advance will ensure that patients who can benefit from our CCM therapy are able to pursue the option without limiting important future diagnostic options.”

The Optimizer Smart Mini delivers CCM therapy to the heart. CCM therapy delivers precisely timed electrical pulses to the heart that are intended to improve the heart’s ability to contract, allowing more oxygen-rich blood to be pushed out through the body.1 CCM therapy is indicated to improve 6-minute hall walk, quality of life, and functional status of NYHA (New York Heart Association) Class III heart failure patients who remain symptomatic despite guideline-directed medical therapy, are not indicated for CRT (cardiac resynchronization therapy), and have a left ventricular ejection fraction ranging from 25 to 45 percent.

The Optimizer Smart Mini incorporates a rechargeable battery with 20-year battery life, offering HF diagnostic monitoring that provides important clinical insights to providers to assist in managing their patients with heart failure. This latest generation also offers internal technology with improved programming and a smaller size designed to make the implant procedure faster and easier for patients and physicians.

Reference

1    Kuschyk J, Falk P, Demming T, et al. Long‐term clinical experience with cardiac contractility modulation therapy delivered by the optimizer smart system. European Journal of Heart Failure. 2021;23(7):1160-1169. doi:10.1002/ejhf.2202

 # # #

About Impulse Dynamics
Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com or follow the company on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

ID-A358-US  

Attachments

Rohan More, Global Vice President of Marketing
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com

Ian Segal, Public and Media Relations
Impulse Dynamics
856-642-9933
isegal@impulsedynamics.com

GlobeNewswire Distribution ID 8968472

Posted on

King Faisal Specialist Hospital and Research Centre Celebrates the Success of Treating 100 Patients with Lymphocytic Leukemia Using CAR T-Cells

King Faisal Specialist Hospital and Research Centre Celebrates the Success of Treating 100 Patients with Lymphocytic Leukemia Using CAR T-Cells

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) — In a new step that offers cancer patients a glimmer of hope and a lifeline, the King Faisal Specialist Hospital and Research Centre (KFSH&RC) celebrated its success in treating the 100th patient with lymphoid leukemia using Chimeric Antigen Receptor T-cell (CAR T-cell) therapy. This aligns with KFSH&RC’s vision to be the optimal choice for specialized healthcare.

CAR T-cell therapy is an innovative treatment that enhances the ability of T-cells to recognize and destroy cancer cells after genetic modification in the laboratory to improve their targeting ability. This approach overcomes the challenge of distinguishing between cancer and normal cells, offering a promising method for treating lymphoid leukemia.

KFSH&RC emphasized that this innovative technology provides hope for patients with resistant leukemia and lymphoid tumors, especially those not effectively treatable with traditional methods.

As a strategic healthcare partner, KFSH&RC is sharing information about CAR T-cell therapy, its positive impact on healthcare improvement, and various healthcare solutions and innovations during the Global Health Exhibition taking place in Riyadh from October 29th to 31st.

KFSH&RC Hospital explained that this advanced therapy consists of four stages: extracting blood from the patient to obtain specific cells, then genetically modifying them in the lab for 3-4 weeks.

Shortly before CAR T-cell therapy, the patient receives a low dose of chemotherapy to enhance its effectiveness and the body’s ability to fight cancer. Afterward, CAR T-cells are infused into the patient’s arm, which is closely monitored for four weeks to ensure the body’s adaptation.

The application of this advanced treatment in the Kingdom represents a qualitative addition to specialized medical care, reducing the financial, social, and health burdens of sending such cases abroad, aligning with Saudi Vision 2030 and its healthcare objectives.

King Faisal Specialist Hospital and Research Centre is globally recognized for offering this advanced form of treatment, thanks to its comprehensive therapeutic program featuring highly skilled medical, nursing, pharmaceutical, laboratory, and social specialists supported by an integrated infrastructure.

KFSH&RC is a global leader in specialized healthcare, innovation, advanced research, and medical education. It aims to develop medical technologies and elevate the standard of healthcare worldwide through partnerships with leading local, regional, and international institutions in clinical, research, and educational fields.

Contact information:
kfshrc@mcsaatchi.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9693817f-f8f6-4535-b14c-41f6801f16f7

GlobeNewswire Distribution ID 8968450

Posted on

King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom

King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom_01

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) — For the past four decades, the Cyclotron and Radiopharmaceuticals Department at King Faisal Specialist Hospital and Research Centre (KFSH&RC) has been addressing the needs of local and regional medical centers for radiopharmaceuticals used in diagnosing and treating various specialized diseases.

Since its establishment, the department has produced over 25 types of radiopharmaceuticals with a production capacity exceeding 600,000 radiopharmaceutical preparations. The department continues to provide its products to over 50 specialized Saudi medical centers, aiming to achieve self-sufficiency in the field of radiopharmaceuticals in the Kingdom of Saudi Arabia.

King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom_02

During the Global Health Exhibition that commenced yesterday in the capital city of Riyadh, where KFSH&RC participates as a strategic health partner, the hospital highlights the department’s pioneering role in nuclear medicine. This includes enhancing the capabilities of healthcare providers in both research and education, as well as ensuring the quality in the production and distribution of radiopharmaceuticals to hospitals across the Kingdom and beyond.

The Cyclotron and Radiopharmaceuticals Department aspires to become a diagnostic and molecular imaging center and the first facility for Technetium-99m (Tc-99m) generators in the Kingdom. It conducts research to develop high-quality radiopharmaceuticals for KFSH&RC and other hospitals throughout the Kingdom to meet all healthcare needs of patients. The department adheres to high-quality standards for automated quality control and assurance while striving to advance cyclotron technology, precise radiopharmaceutical manufacturing, and the development of radiopharmaceuticals used in positron emission tomography/computed tomography (PET/CT).

The department significantly emphasizes quality, with an integrated product quality control and management unit, manufacturing materials following Good Manufacturing Practices (GMP), the Saudi Food and Drug Authority (SFDA) standards, and ISO 9001 international quality management system standards. All operational processes are subjected to rigorous monitoring for the periodic evaluation of materials, ensuring their continuous suitability. This approach has led to a remarkable customer satisfaction rate exceeding 95%.

KFSH&RC is globally recognized for providing specialized healthcare and is a leader in innovation, advanced medical research, and medical education. The institution actively seeks to develop medical technologies and enhance the standard of healthcare worldwide, partnering with leading local, regional, and international organizations to deliver world-class services in clinical, research, and educational domains.

Contact information:
kfshrc@mcsaatchi.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/ad78d2ea-0d15-45ae-a3bd-cd25f7bf7ab9

https://www.globenewswire.com/NewsRoom/AttachmentNg/1d1f90e9-3a44-43cf-8812-af6760e2d0b2

GlobeNewswire Distribution ID 8968426

Posted on

Zoom AI Companion hits one million meeting summaries milestone

AI Companion will expand support for 32 new languages, new capabilities for Zoom Events, in-meeting questions, and meeting coaching

SAN JOSE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — Today Zoom Video Communications, Inc. (NASDAQ: ZM) announced that Zoom AI Companion, the company’s generative AI assistant, has reached a milestone less than two months after its launch, with more than 125,000 accounts using AI Companion, generating more than one million meeting summaries. Zoom also announced new capabilities, additional language support, and further enhancements to existing capabilities for AI Companion.

“Providing the best value to our customers across our platform is core to our mission, which is why we made AI Companion available at no additional cost,1 and we continue to introduce new AI capabilities at Zoom speed, so more of our customers can get the most out of Zoom’s AI innovations,” said Smita Hashim, chief product officer at Zoom. “Our unique federated approach allows us to dynamically utilize different models, helping to reduce AI overhead costs and provide broad access to generative AI.”

New Zoom AI Companion capabilities
Beginning today, AI Companion users will be able to use the in-meeting questions capability in new languages, as well as receive short meeting summary overviews at the beginning of full meeting summaries.

  • Users can now use AI Companion’s in-meeting questions capability in seven new languages (preview).
  • Based on feedback from users, the meeting summaries capability now includes an overview at the top of the summary in emailed summaries, providing users with a shorter version of the meeting summary in addition to the full meeting summary. Meeting summary overviews will be available in summaries delivered via continuous meeting chat in November.

AI Companion capabilities available in November

Zoom will continue to improve AI Companion, with the following new capabilities planned to be available in November:

  • Both AI Companion meeting summary and in-meeting questions capabilities will support a total of 32 new languages, in preview.
  • AI Companion will provide users with meeting coach capabilities, beginning with speech analytics in Smart Recordings. Speech analytics will include the meeting host’s talk-listen ratio, talk speed, and speech fillers so that hosts can glean valuable insights into how they engage with meeting participants during Zoom Meetings.
  • AI Companion will be available in Zoom Events, with chat compose capabilities for lobby chats and assistance with composing emails for registration, marketing, and ticketing communications.
  • Zoom will introduce an optional control for customers to specify that AI Companion capabilities for their organization only use the Zoom large language model.

What Zoom customers are saying about AI Companion

“AI Companion’s meeting summaries and smart recordings are the first technological innovations in the last decade that bring us tangible time-saving, efficient benefits. People can prioritize specific meetings and collaborations while remaining confident they aren’t missing out on competing activities.” – Chris Blackstone, director, Digital Workplace and End User Computing, Convera

“Zoom’s AI Companion meeting summary tool is helping us become better communicators. Guided by its impressively accurate output, our teams are more consistently adhering to best practices in meetings such as stating the objective upfront and clearly outlining and assigning action items. Plus, we were able to save money by offboarding a vendor and save time by not having to produce meeting notes ourselves.” – Lucas Oliveira, COO, Bizzycar, Inc.

“Meeting summaries has saved our team a ton of time. We feel that everyone is in the loop without necessarily having to attend every meeting, which results in better collaboration.” – Karl Morsgofian, CIO, Gainsight

“Zoom’s AI Companion exemplifies our vision for enhanced collaboration and innovation. With automated, detailed meeting summaries, it streamlines information sharing and boosts productivity. This inclusion in our Zoom plan not only improves efficiency but also yields significant cost savings, reflecting our commitment to a smarter, more connected future.” – John Georgatos, CIO, Mike Morse Law Firm

AI Companion is available for eligible paid Zoom user accounts at no additional cost.1 For more information about Zoom AI Companion, visit the Zoom website.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Forward-Looking Statements

This press release contains express and implied “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits and potential of Zoom’s generative AI assistant. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “will,” “would,” “should,” “could,” “can,” “predict,” “potential,” “target,” “explore,” “continue,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, including those described under the caption “Risk Factors” and elsewhere in our most recent filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the fiscal quarter ended July 31, 2023. Forward-looking statements speak only as of the date the statements are made and are based on information available to Zoom at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Zoom assumes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, except as required by law.

Zoom Public Relations
Lacretia Taylor
press@zoom.us

1 Note: Included at no additional cost with the paid services assigned to Zoom accounts. AI Companion may not be available for all regions and industry verticals.

GlobeNewswire Distribution ID 8968304